Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Laura Marcos-Kovandzic"'
Autor:
Cathy Pichol-Thievend, Oceane Anezo, Aafrin M. Pettiwala, Guillaume Bourmeau, Remi Montagne, Anne-Marie Lyne, Pierre-Olivier Guichet, Pauline Deshors, Alberto Ballestín, Benjamin Blanchard, Juliette Reveilles, Vidhya M. Ravi, Kevin Joseph, Dieter H. Heiland, Boris Julien, Sophie Leboucher, Laetitia Besse, Patricia Legoix, Florent Dingli, Stephane Liva, Damarys Loew, Elisa Giani, Valentino Ribecco, Charita Furumaya, Laura Marcos-Kovandzic, Konstantin Masliantsev, Thomas Daubon, Lin Wang, Aaron A. Diaz, Oliver Schnell, Jürgen Beck, Nicolas Servant, Lucie Karayan-Tapon, Florence M. G. Cavalli, Giorgio Seano
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-27 (2024)
Abstract Glioblastoma (GBM) is a highly lethal type of cancer. GBM recurrence following chemoradiation is typically attributed to the regrowth of invasive and resistant cells. Therefore, there is a pressing need to gain a deeper understanding of the
Externí odkaz:
https://doaj.org/article/3b619e0cc25442dda280674d2cd28cb1
Autor:
Daniel Herrero Rivera, Carmen Garrigós Vacas, Laura Marcos Kovandzic, Javier Puente Vázquez, Lucía A Alonso, Begoña Mellado González, Verónica Calderero Aragón, Enrique Grande, Raquel Luque Caro, Juan A Virizuela Echaburu, Juan F Rodríguez Moreno, Ainara A Etxebarria, Cristina Rodríguez-Antona, Ignacio Durán
Publikováno v:
Pharmacogenomics. 23:627-638
[Background The aim of this study was to evaluate the impact of certain single-nucleotide polymorphisms (SNPs) in cabazitaxel activity and tox]icity in patients with metastatic castration-resistant prostate cancer (mCRPC).
[Patients & methods] 5
[Patients & methods] 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48f86220b423a982c514f09867766e22
https://doi.org/10.2217/pgs-2022-0023
https://doi.org/10.2217/pgs-2022-0023
Autor:
Lucia Alonso Buznego, Enrique Grande, Javier Puente, Begoña Mellado, Juan Francisco Rodriguez-Moreno, Laura Marcos Kovandzic, Ainara Azueta, Ignacio Duran, Daniel Rivera, Juan Antonio Virizuela, Carmen Garrigos, Raquel Luque
Publikováno v:
Journal of Clinical Oncology. 38:e17582-e17582
e17582 Background: Cabazitaxel is a semi-synthetic derivative of a natural taxoid approved for the treatment of mCRPC patients (pts) after failure to docetaxel. Despite its proven efficacy, there is variability in the response, progression-free survi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef7979098857bdb3f4ba3cfdcec4ffab
https://doi.org/10.1200/jco.2020.38.15_suppl.e17582
https://doi.org/10.1200/jco.2020.38.15_suppl.e17582